EULAR 2022 Top 10 Abstracts (6.10.2022)

Save

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty.

CV risk factors not equal when considering magnitude of risk

Save

What can we learn from Oral Surveillance?

The Oral Surveillance trial has almost become a household word for rheumatologists.

Can we stop RA before it happens?

Save

Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals.

Gout Undertreatment Persists

Save

Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.

The Safety of Rituximab and JAK Inhibitors with post-COVID Vaccination

Save

At the onset of the pandemic, data from the Global Rheumatology Alliance reported increased risk of poor severe COVID outcomes including deaths in patients who were treated with rituximab and baricitinib. With the vaccination program undertaken globally, has this risk been attenuated?

Is Pain Control by Cannabis an Option?

Save

An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation.